Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

University of Toronto

$122,500.00

Optimization, scale-up, stability, and manufacture of a hydrogel for local, sustained delivery - phase I

EF 2016-17

Résumé
Hammock Therapeutics is a Toronto-based biotechnology company focused on developing and commercializing a unique hydrogel platform technology for medical applications. Hammock Therapeutics represents a unique opportunity for the commercialization of combination products at the interface of biomaterials and pharmaceuticals. The lead program for the company is to develop a product to overcome post-operative pain, an unmet clinical and market need with a clear path to market. Our first product is aimed at controlling post-operative pain. Acute post-operative pain remains a clinical challenge as current treatment strategies do not meet patient needs. There is a clear market gap that our product will address and there are numerous clinical applications associated with post-operative pain. To address all of the proposed applications it is essential to develop manufacturing methodologies, which allow for scale-up in order to produce a clinical grade product. Building on the prototype already established, this project partners with a pharmaceutical contract manufacturing and drug development research company to develop the standard operating procedures (SOPs) to manufacture our product under cGMP conditions.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
493938-2016
Name nom
Shoichet, Molly
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
122500
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Optimization, scale-up, stability, and manufacture of a hydrogel for local, sustained delivery - phase I
Keyword
NSERC
Application summary
Hammock Therapeutics is a Toronto-based biotechnology company focused on developing and commercializing a unique hydrogel platform technology for medical applications. Hammock Therapeutics represents a unique opportunity for the commercialization of combination products at the interface of biomaterials and pharmaceuticals. The lead program for the company is to develop a product to overcome post-operative pain, an unmet clinical and market need with a clear path to market. Our first product is aimed at controlling post-operative pain. Acute post-operative pain remains a clinical challenge as current treatment strategies do not meet patient needs. There is a clear market gap that our product will address and there are numerous clinical applications associated with post-operative pain. To address all of the proposed applications it is essential to develop manufacturing methodologies, which allow for scale-up in order to produce a clinical grade product. Building on the prototype already established, this project partners with a pharmaceutical contract manufacturing and drug development research company to develop the standard operating procedures (SOPs) to manufacture our product under cGMP conditions.